All In Biotech

Investigational drug · Phase 2

TXN10128

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for NSCLC (Non-small Cell Lung Cancer).

Phase 2

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

2

Any phase or sponsor naming "TXN10128"

First trial start

2026

Oct 8, 2026

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "TXN10128", any sponsor or status.

Conditions studied

As listed on its trial records.

  • NSCLC (Non-small Cell Lung Cancer)

Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Oncology

Largest trials

Live from ClinicalTrials.gov: studies naming "TXN10128" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for NSCLC (Non-small Cell Lung Cancer)

  • AndamertinibPLB1004Phase 38 trials

    Avistone Biotechnology Co., Ltd. · Non-Small-Cell Lung Cancer, NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer

  • OSE2101Phase 32 trials

    OSE Immunotherapeutics · Patients With Non-Small Cell Lung Cancer, Solid Advanced Tumor, Lymphoma

  • SugemalimabPhase 32 trials

    Akeso · NSCLC (Non-small Cell Lung Cancer), Extranodal NK/T-cell Lymphoma

  • JMKX001899Phase 31 trial

    Jemincare · NSCLC (Non-small Cell Lung Cancer)

  • IAM1363Phase 21 trial

    Iambic Therapeutics, Inc · HER2 Mutation-Related Tumors, HER2, HER2-positive Breast Cancer

  • OSE-279Phase 21 trial

    OSE Immunotherapeutics · Solid Advanced Tumor, Lymphoma, NSCLC (Non-small Cell Lung Cancer)

  • YH42946Phase 21 trial

    Yuhan Corporation · NSCLC (Non-small Cell Lung Cancer), Solid Tumor

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.